Table 4.
Induced chemotherapy response and recovery time of BMHF in newly diagnosed AML patients with and without BMF.
| Treatment response | AML with BMF | AML without BMF | P value |
|---|---|---|---|
| CR/CRi, n (%) | 51 (54.25%) | 44 (77.19%) | 0.004 |
| CR, n (%) | 37 (39.36%) | 35 (61.40%) | 0.008 |
| CRi, n (%) | 14 (14.89%) | 9 (15.79%) | 0.883 |
| PR, n (%) | 21 (22.34%) | 9 (15.78%) | 0.331 |
| Induction failure, n (%) | 22 (23.40%) | 4 (7.02%) | 0.010 |
| Abandoning therapy, (n) | 36 | 3 | |
| Recovery time of BMHF | |||
| CR/CRi a, day, median (range) | 26 (13~73) | 22 (7~61) | 0.034 |
| CR b, day, median (range) | 24 (13~73) | 22 (7~61) | 0.067 |
AML, acute myeloid leukemia; BMF, bone marrow fibrosis; CR, complete remission; CRi, morphologic complete remission with incomplete blood count recovery; PR, partial remission. athe recovery time of bone marrow hematopoietic function in patients achieving CR/CRi; bthe recovery time of bone marrow hematopoietic function in patients achieving CR.